NEW BRUNSWICK, N.J. / Jul 10, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Celine Martin, Company Group Chairman Cardiovascular & Specialty Solutions Group (CSS), Anthony (Tony) Long, VP, Clinical Research, Medical Affairs, Preclinical Research and Jasmina Brooks, President Biosense Webster will represent the Company in a session scheduled at 2:00 pm (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
A webcast replay will be available approximately 48-hrs after the live webcast.
| Last Trade: | US$162.99 |
| Daily Change: | 0.14 0.09 |
| Daily Volume: | 4,992,386 |
| Market Cap: | US$392.810B |
March 08, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
